Immunotherapy Efficacy in SMARC-Altered Cancers: A pan-cancer analysis of clinical outcomes in response to immune checkpoint inhibition
Authors:
- Gregory P. BottaGBGregory P. Botta
- Wesleigh EdwardsWEWesleigh Edwards
- Daisuke NishizakiDNDaisuke Nishizaki
- Diana C. HargreavesDHDiana C. Hargreaves
- Shumei KatoSKShumei Kato
- Razelle KurzrockRKRazelle Kurzrock
Open Access
Abstract
No abstract availableFunding Information
- National Cancer Institute (P30CA023100)
- National Institutes of Health (KL2TR002552)
This publication has 42 references indexed in Scilit:
- ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunityCell, 2024
- Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary CarcinomaCancer Cell, 2020
- Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trialThe Lancet Oncology, 2020
- Clonally Expanded T Cells Reveal Immunogenicity of Rhabdoid TumorsCancer Cell, 2019
- Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell InfiltrationCell Reports, 2019
- Checkpoint inhibitors in pancreatic cancerCancer Treatment Reviews, 2019
- Functional loss of ARID1A is tightly associated with high PD‐L1 expression in gastric cancerInternational Journal of Cancer, 2019
- ATP-dependent chromatin remodeling: genetics, genomics and mechanismsCell Research, 2011
- Truncating mutations of hSNF5/INI1 in aggressive paediatric cancerNature, 1998
- Repetitive extragenic palindromic sequences: A major component of the bacterial genomeCell, 1984